This article is more than 5 years old. Information may no longer be current.

Allergan, Senju Pharmaceutical to market Lumigan in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

OSAKA, Japan — Allergan Inc. and Senju Pharmaceuticals have agreed to jointly develop and market Lumigan for the Japanese glaucoma market, the companies announced.

Lumigan (bimatoprost ophthalmic solution, 0.03%) is currently in phase 3 clinical development in Japan, with market approval expected in 2007, the companies said in a joint press release.

According to the press release, Senju will be responsible for development and commercialization of Lumigan in Japan and will incur the associated costs. Senju will provide Allergan with an up-front payment as well as milestone payments related to development and commercialization. Senju will also pay royalties to Allergan based on Japanese drug sales following commercialization. Both companies will work together on overall product strategy and management, the release said.